Get started
Author

Mark A. Tye

Observed names: M. Tye, Mark A Tye
Observed institutions: University of Nebraska–Lincoln, Harvard University, Massachusetts General Hospital, Revolution Medicines (United States), Center for Systems Biology, Harvard-MIT Center for Regulatory Science
ORCID: 0000-0002-9456-0767
Observed ORCID: 0000-0002-9456-0767
OpenAlex ID: A5078323744
AI is a viable alternative to high throughput screening: a 318-target study
2024 · The Atomwise AIMS Program, Izhar Wallach, et al. · Scientific Reports · 143
Bright and stable luminescent probes for target engagement profiling in live cells
2021 · N. Connor Payne, Alena S. Kalyakina, et al. · Nature Chemical Biology · 72
Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance
2022 · Mark A. Tye, N. Connor Payne, et al. · Nature Communications · 33
PDF
The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection
2021 · Daniel R. Sandoval, Thomas Mandel Clausen, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 22
PDF
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
2023 · Keiji Kurata, Anna James-Bott, et al. · Blood Cancer Journal · 21
PDF
Advances in malaria pharmacology and the online guide to MALARIA PHARMACOLOGY: IUPHAR review 38
2023 · Jane F. Armstrong, Brice Campo, et al. · British Journal of Pharmacology · 14
PDF
Considerations for the Selection and Use of Disinfectants Against SARS-CoV-2 in a Health Care Setting
2020 · Kevin Tyan, Adriane Levin, et al. · Open Forum Infectious Diseases · 7
PDF
Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance
2023 · Rebecca E.K. Mandt, Madeline R. Luth, et al. · eLife · 6
PDF
Disruption of P. falciparum amino acid transporter elevates intracellular proline and induces resistance to Prolyl-tRNA synthetase inhibitors
2025 · Selina Bopp, Lọla Fagbami, et al. · Cell chemical biology · 3
Author Correction: AI is a viable alternative to high throughput screening: a 318-target study
2024 · The Atomwise AIMS Program, Izhar Wallach, et al. · Scientific Reports · 3
PDF
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
2023 · Keiji Kurata, Anna James-Bott, et al. · Blood Cancer Journal · 2
PDF
Discovery of Zoldonrasib (RMC-9805), a Potent and Orally Bioavailable RAS(ON) G12D-Selective, Covalent, Tri-Complex Inhibitor for the Treatment of Patients with RAS G12D-Addicted Cancers
2026 · G. Leslie Burnett, Caroline Weller, et al. · Journal of Medicinal Chemistry
Author response: Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance
2023 · Rebecca EK Mandt, Madeline R Luth, et al. · eLife
PDF
Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma
2021 · Keiji Kurata, Anna-James Bott, et al. · Blood
Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline--tRNA ligase) from Plasmodium falciparum in complex with NCP-26 and L-Proline
2019 · C. Johansson, J. Wang, et al. · Worldwide Protein Data Bank
Works count: 15
Citation count: 326
H-index: 7
I10-index: 6
Year
Topic
Type